FORMULATION ARTICLES

FORMULATION VIDEOS

Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

Explore the future of nucleic acid and nanoparticle-based therapeutics, including mRNA, CRISPR, and gene editing, as experts discuss innovative solutions for complex health challenges.

In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS